Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | TCF4 | P15884 | 1/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29942396 | 1.00 | F2 (0.37) | F2PRSS1PRSS2PRSS3POLB | |
| SCHEMBL25283314 | 0.85 | F2 (0.37) | F2PRSS1PRSS2PRSS3POLB | |
| SCHEMBL23755933 | 0.85 | F2 (0.37) | F2PRSS1PRSS2PRSS3POLB | |
| SCHEMBL29942313 | 0.83 | CA12 (0.41) | POLBCA1CA2MAPTALDH1A1 | |
| SCHEMBL23756490 | 0.83 | CA12 (0.41) | POLBCA1CA2MAPTALDH1A1 | |
| SCHEMBL30204282 | 0.81 | TCF4 (0.40) | F2PRSS1PRSS2PRSS3POLB | |
| SCHEMBL5230240 | 0.81 | TCF4 (0.40) | F2PRSS1PRSS2PRSS3POLB | |
| SCHEMBL23320398 | 0.77 | RAPGEF4 (0.35) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL31309368 | 0.76 | CYP2C9 (0.36) | F2PRSS1PRSS2PRSS3POLB | |
| SCHEMBL23320425 | 0.76 | CYP2C9 (0.43) | F2PRSS1PRSS2PRSS3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4103559-B1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12473304-B2 | Heterocyclic PAD4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250136607-A1 | PAD4 INHIBITORS AND USE THEREOF | REGOR PHARMACEUTICALS, INC. | 2025-05-01 | — | — | US | disclosed |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-01 | — | — | US | disclosed |
| EP-4103559-A1 | HETEROCYCLIC PAD4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-12-21 | — | — | EP | disclosed |
| CN-115348961-A | Heterocyclic PAD4 inhibitors | 百时美施贵宝公司 | 2022-11-15 | — | — | CN | disclosed |
| WO-2021163254-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473304-B2 | Heterocyclic PAD4 inhibitors | PADI6, PADI4, PADI1 | F2 1669/4885PRSS1 684/4885PRSS2 1536/4885 |
| US-20250136607-A1 | PAD4 INHIBITORS AND USE THEREOF | PADI4, PADI6, PADI2 | F2 4604/4885PRSS1 394/4885PRSS2 749/4885 |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI2, PADI6 | F2 2631/4885PRSS1 1019/4885PRSS2 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.